Project description:Identification of bladder cancer subsets 142 primary bladder tumors including superficial and invasive tumors were arrayed. 73 invasive tumors out of 142 tumors were used for muscle invasive baldder cancer classification
Project description:We aimed to provide a molecular description of Lynch syndrome-associated urothelial cancer in relation to molecular subtypes of sporadic bladder cancer. Whole genome mRNA expression profiles of 41 tumors and immunohistochemical stainings against FGFR3, KRT5, CCNB1, RB1, and CDKN2A (p16) of 37 tumors from Lynch syndrome patients were generated. Pathological data, microsatellite instability, anatomic location, and overall survival data was analyzed and compared with data from sporadic bladder cancer.
Project description:Purpose: The goals of this study are to compare 1. The transcription profile in KDM6A wildtype and KDM6A mutated urothelial bladder carcinoma. 2. The transcriptional changes in KDM6A mutated urothelial bladder carcinoma upon EZH2 inhibitor treatment.
Project description:Bladder cancer is a major and mortal disease in urological area. Cisplatin is a key drug for bladder cancer especially for muscle invasive cases. In most cases of bladder cancer, cisplatin is effective; however, resistance to cisplatin is critical for patient’s prognosis. Thus, treatment strategy for cisplatin resistant bladder cancer is essential to improve current prognosis. In this study, we established cisplatin resistant bladder cancer line (CR cells) using a urothelial carcinoma line UM-UC-3 cells. We screened potential targets for CR cells and found that claspin is overexpressed in CR cells. Claspin mRNA knockdown revealed that claspin has a role in cisplatin resistance in CR cells. In our previous study, we found HLA-A*02:01-restricted CLSPN peptide by an HLA ligandome analysis. We thus generated CLSPN peptide specific CTL clone and found that CLSPN peptide-specific CTL clone recognized CR cells at higher levels compared with that of UM-UC-3 wild type cells. These findings indicate that claspin is a driver for cisplatin resistance and claspin peptide-specific immunotherapy is effective for cisplatin resistant cases.
Project description:Histological variation is a common feature of metastatic cancer but its clonal origins and impact on disease history remains poorly defined. In this study, we developed a first-in-kind metastatic bladder cancer (BLCA) rapid autopsy cohort enriched in rare histological subtypes to extensively profile individuals with terminal disease. By reconstructing the evolutionary history of patient tumors, we determined that metastasis-to-metastasis seeding was the dominant driver of cancer spread and that increased polyclonal migration contributed to poor prognosis. The burden, heterogeneity, and timing of acquired genomic alterations were markedly different between histological subtypes. Plasmacytoid and neuroendocrine variants developed early genomic driver alterations that associated with shorter survival. Mutational signature analysis further revealed that plasmacytoid, but not other subtypes, utilized the Fanconi Anemia pathway to shield from chemotherapy-induced genomic scarring. Using experimental models, we demonstrated that Fanconi Anemia pathway activity positively correlated with resistance to cisplatin chemotherapy, demonstrating a molecular basis for therapy resistance in plasmacytoid patients. We report the first single-nucleus profiling of mBLCA histological subtypes, revealing mixed cell states in plasmacytoid tumors and that increased overall transcriptional heterogeneity was associated with longer patient survival. Characterization of the tumor microenvironment uncovered distinct patterns of immune activation across histological subtypes, with plasmacytoid tumors exhibiting an immune-inflamed profile, while squamous subtype was dominated by immunosuppressive interactions. Lastly, we demonstrated that post-mortem cell-free DNA captured both genomic heterogeneity and transcriptional activity of the subtypes, providing a potential strategy to non-invasively assess tumor identity and aggressiveness in patients with mBLCA. Our results provide new principles into how tumor heterogeneity shapes the evolutionary history of cancer progression within subtypes of human bladder cancer
Project description:Comprehensive evaluation of human cell lines for the transcription dynamics in response to the inhibition of PKC isozymes ε & ζ in bladder cancer.